Skip to main
MOLN

MOLN Stock Forecast & Price Target

MOLN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Molecular Partners is a clinical-stage biopharmaceutical company with a robust pipeline of clinical and preclinical programs in the field of oncology, specifically targeting DLL3. With radiotheranostics being viewed as a field with strong future potential and an estimated market size of $1.7 billion to $6.0 billion, Molecular Partners has the potential to capture a significant portion of this market and generate substantial revenue. The recent FDA approval of a DLL3-targeted therapy from Amgen further validates the potential success of therapies targeting DLL3 and Molecular Partners' approach with MP0712. Risks include negative clinical results, delays in advancing pipeline candidates, and competitive risks.

Bears say

Molecular Partners is facing financial challenges as they plan a follow-on offering in October 2024, indicating a potential future cash flow deficit as they await clinical trial successes and life-saving regulatory approvals for their flagship products. The biopharma industry is strongly regulated and subject to government intervention as seen in the company's previous experience, posing risks to their future operations. Additionally, the company may struggle to achieve profitability and market share against well-established competitors and may face challenges in effectively penetrating target markets due to limited commercial infrastructure.

MOLN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Molecular Partners AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Molecular Partners AG (MOLN) Forecast

Analysts have given MOLN a Buy based on their latest research and market trends.

According to 2 analysts, MOLN has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Molecular Partners AG (MOLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.